Dockets
Federal rulemakings, soonest-closing first — each gathers its documents and comments.
Agency ▾
Requests that the FDA conduct “[a] study to determine the necessity for the development of standards for the use of nonmedical electronic products for commercial and industrial purposes” and provide a report to Congress
Requests that the FDA take the following measures to protect the public from mercury exposure and other risks caused by dental amalgam: (1) Ban dental amalgam, (2) Ban the use of dental amalgam at least in high-risk populations, including children, pregnant women, women who are planning to become pregnant, nursing women, people with neurological disease, people with impaired kidney function
Charter Server Complaints
Matthew T. Keefe - Exemption/Rulemaking
Amor Fati Industries Corp. - Exemption/Rulemaking
Federal Registers for Applications, Notices, and Orders - Miscellaneous
NetJets Aviation, Inc - Exemption/Rulemaking
1 awaiting analysis
Requesting that the FDA make changes to an existing Guidance for Industry requirement by amending the regulation in this way: 10. How are Spices, natural flavors or artificial flavors declared in ingredients lists Answer: These may be declared in ingredient lists by using either specific common or scientific names. All products or ingredients of products that are spices
Requests that the FDA to remove oral diphenhydramine from all over-the counter cough, cold and allergy products.
Requests that the FDA Reverse its decision to classify desiccated thyroid extract (DTE) as a biological product under the PHS Act; Clarify that the August 6, 2025 Notice to Industry; Affirm that natural thyroid products should, if approved, proceed through the drug approval pathway under section 505 of the FD&C Act; regarding the classification and regulation of DTE products
Request that FDA remove the Mifepristone Shared System REMS Program, including but not limited to the three ETASU requiring prescriber certification, pharmacy certification, and a patient agreement form
Request that the FDA remove the Mifepristone REMS Program, including but not limited to the Prescriber Certification, Pharmacy Certification, and Patient Agreement form